Pharmaceutical Ending a four year investigation, US health care major Abbott Laboratories (NYSE: ABT) has reached a settlement with US federal and 49 state authorities, plus the District of Columbia, to resolve all outstanding issues regarding a previously disclosed investigation of past sales and marketing practices relating to its Depakote (divalproex), approved for the treatment of for the treatment of epilepsy, bipolar disorder and migraine 8 May 2012